The rational design of an AIDS vaccine
- PMID: 16497577
- DOI: 10.1016/j.cell.2006.02.005
The rational design of an AIDS vaccine
Abstract
The extraordinary genetic diversity and immune evasion of human immunodeficiency virus (HIV) pose significant challenges for vaccine development. AIDS vaccine design requires a scientifically driven, rational approach that encompasses the latest advances in viral molecular genetics, structural biology, and immunology.
Similar articles
-
India targets local HIV strain in test of AIDS vaccine.Nature. 2004 Jan 15;427(6971):185. doi: 10.1038/427185b. Nature. 2004. PMID: 14724601 No abstract available.
-
Is an effective HIV vaccine feasible?Science. 2005 Jul 1;309(5731):99. doi: 10.1126/science.309.5731.99. Science. 2005. PMID: 15994545 No abstract available.
-
Progress toward an HIV vaccine.Annu Rev Med. 2005;56:213-23. doi: 10.1146/annurev.med.54.101601.152349. Annu Rev Med. 2005. PMID: 15660510 Review.
-
New hope for an AIDS vaccine.Nat Rev Immunol. 2002 Apr;2(4):239-50. doi: 10.1038/nri776. Nat Rev Immunol. 2002. PMID: 12001995 Review.
-
Human immunodeficiency virus antibodies and the vaccine problem.J Intern Med. 2014 May;275(5):444-55. doi: 10.1111/joim.12225. J Intern Med. 2014. PMID: 24581142 Review.
Cited by
-
Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.J AIDS Clin Res. 2012;S8:3. doi: 10.4172/2155-6113. Epub 2012 Mar 22. J AIDS Clin Res. 2012. PMID: 23227445 Free PMC article.
-
An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene.Emerg Microbes Infect. 2016 Jun 22;5(6):e65. doi: 10.1038/emi.2016.86. Emerg Microbes Infect. 2016. PMID: 27329850 Free PMC article.
-
Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine.Toxins (Basel). 2022 Feb 14;14(2):138. doi: 10.3390/toxins14020138. Toxins (Basel). 2022. PMID: 35202165 Free PMC article. Review.
-
Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease.J Biol Chem. 2011 Apr 8;286(14):12133-40. doi: 10.1074/jbc.M110.191148. Epub 2011 Feb 4. J Biol Chem. 2011. PMID: 21296887 Free PMC article.
-
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.J Infect Dis. 2008 Jun 15;197(12):1634-42. doi: 10.1086/588385. J Infect Dis. 2008. PMID: 18444883 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical